The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.
Ip MS. Update on the current treatment of diabetic retinopathy. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...
It's a daycare procedure and doesn't require hospitalisation. However, it is an expensive treatment. Will my health insurance ...
Diabetes affects millions worldwide, and while most know about its impact on blood sugar and organ health, vision loss ...
Experiencing fatigue, blurred vision, and unexplained weight loss, a young man sought medical consultation and was informed ...
This condition is called diabetic retinopathy. In its early stages ... making regular eye exams crucial for early detection ...
The study failed its primary objective of showing a reduction in the severity of diabetic retinopathy after 24 ... end-to-end solution that can develop drugs from the discovery process through ...
About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...
Insurance coverage for intravitreal injections, an essential treatment for diabetic retinopathy, depends on the specific terms and conditions of an individual’s health insurance policy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback